Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe

AIDS

Volumn 13, Issue 8, 1999, Pages 943-950

  Mocroft, Amanda ^a   Kirk, Ole ^b   Barton, Simon E ^c   Dietrich, Manfred ^d   Proenca, Rui ^e   Colebunders, Robert ^f   Pradier, Cristian ^g   D'Arminio Monforte, Antonella ^h   Ledergerber, Bruno ⁱ   Lundgren, Jens D ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HVIDOVRE HOSPITAL   (Denmark)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^e HOSPITAL CURRY CABRAL   (Portugal)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anaemia; CD4 count; Mortality; Viral load

Indexed keywords

CD4 ANTIGEN; HEMOGLOBIN;

ADULT; ANEMIA; ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; DISEASE COURSE; EUROPE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL; VIRUS LOAD;

EID: 20244375228     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905280-00010     Document Type: Article

References (41)

1. Chene G, Fasterbrook PJ, Jusczak E, et al. Long-term survival in patients with advanced immunodeficiency. AIDS 1997, 11:209-216.
2. Swanson CE, Cooper DA (for the Australian zidovudine study group). Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia. AIDS 1990, 4:749-757.
3. 6/l. AIDS 1995, 9:145-152.
4. Rezza G, Lazzarin A, Angarano G, et al. The natural history of HIV infection in intravenous drug users: risk of progression in a cohort of seroconverters. AIDS 1989, 3:87-90.
5. Hoover DR, Saah A, Bacellar H, et al. The progression of untreated HIV-1 infection prior to AIDS. Am J Public Health 1992, 82:1538-1541.
6. Saah AJ, Hoover DR, He Y, Kingsley IA, Phair JP Factors influencing survival after AIDS: report from the Multicentre AIDS Cohort Study (MACS). J Acquire Immun Defic Synd 1994, 7:287-295.
7. Rabeneck L, Hartigan PM, Huang IW, Souchek J, Wray NP Predicting outcomes in HIV-infected veterans: II. Survival after AIDS. J Clin Epidemiol 1997, 50:1241-1248.
8. Creagh-Kirk T, Doi P, Andrews E, et al. Survival experience among patients with AIDS receiving zidovudine - follow-up of patients in a compassionate plea program. JAMA 1988, 260:3009-3015.
9. Swanson CE, Tindall B, Cooper DA Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. AIDS 1994, 8:625-634.
10. Apolonio EG, Hoover DR, He Y, et al. Prognostic factors in human immunodeficiency virus-positive patients with a CD4+ lymphocyte count <50/μl. J Infect Dis 1995, 171:829-836.
11. Turner BJ, Markson L, Taroni F Estimation of survival after AIDS diagnosis. CD4 T Lymphocyte count versus clinical severity. J Clin Epidemiol 1996, 49:59-65.
12. 3. J AIDS 1997, 15:346-355.
13. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantification of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
14. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV infection. Ann Intern Med 1997, 126:946-954.
15. Phillips AN, Eron JJ, Bartlett JA, et al. HIV-1 RNA levels and the development of clinical disease. AIDS 1996, 10:859-865.
16. Coombs RW, Welles SL, Cooper C, et al. Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996, 174:704-712.
17. Moore RD, Keruly JC, Chaisson RE, et al. Anemia and survival in HIV infection. J AIDS 1998, 19:29-33.
18. Phillips AN, Lee CA, Elford J, et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991, 337:389-392.
19. Munoz A, Carey V, Saah AJ, et al. Predictors of decline in CD4 lymphocytes in a cohort of homosexual men infected with human immunodeficiency virus. J Acquir Immune Defic Synd 1988, 1:396-404.
20. Montella F, Di Sora F, Perrucci CA, Abeni DD, Recchia O T-lymphocyte subsets in intravenous drug users with HIV-1 infection (letter). JAMA 1992, 268:2516-2517.
21. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W The characterisation of non-progressors: long term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993, 7:1159-1166.
22. Margolick JB, Munoz A, Vlahov D, et al. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA 1992, 267:1631-1636.
23. Easterbrook PJ, Emami J, Gazzard B. Rate of CD4 cell decline and prediction of survival in zidovudine treated patients. AIDS 1993, 7:959-967.
24. Lundgren JD, Phillips AN, Vella S, et al. Regional differences in the use of antiretrovirals and primary prophylaxis in 3122 European HIV-infected patients. J AIDS 1997, 16:153-160.
25. Phillips AN, Katlama C, Barton S, et al. Survival in 2367 zidovudine treated patients according to use of other nucleoside analogue drugs. J AIDS 1998, 17:239-244.
26. Center for Disease Control 1993 revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults. MMWR 1992, 41(RR-17):1-19.
27. nd edn, edited by Hoffman R, Benz EJ, Shattil SJ, et al. Edinburgh: Churchill Livingstone; 1995:468-483.
28. Kaplan EL, Meier P Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
29. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall; 1984.
30. SAS Institute Inc. SAS/STAT Users Guide, Version 6, 4th edn, Vol. 2. Cary, NC: SAS Institute Inc.; 1989.
31. Rabeneck L, Hartigan PM, Huang IW, Souchek J, Wray NP Predicting outcomes in HIV-infected veterans: I. Progression to AIDS. J Clin Epidemiol 1997, 50:1231-1240.
32. Grant AD, Djomand G, Smets P, et al. Profound immunosupression across the spectrum of opportunistic disease among hospitalised HIV-infected adults in Abidjan, Cote d'Ivoire. AIDS 1997, 11:1357-1364.
33. Lifson AR, Allen S, Wolf W, et al. Classification of HIV disease in women from Rwanda. Ann Intern Med 1995, 122:262-270.
34. Kirk O, Mocroft A, Katzenstein T, et al. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS 1998, 12:2031-2039.
35. Coyle IE Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med Clin North Am 1997, 81:449-470
36. Hambleton J Hematologic complications of HIV infection. Oncology 1996, 10:671-680.
37. Sullivan P, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998, 91:301-308.
38. Ledru E, Diagbouga S, Meda N, et al. A proposal for basic management of HIV disease in West Africa: use of clinical staging and haemogram data. Int J STD AIDS, 1998:463-470.
39. + lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992, 165:352-363.
40. Mocroft A, Johnson MA, Sabin CA, et al. The relationship between beta-2-microglobulin, CD4 lymphocyte count, AIDS and death in HIV-positive individuals. Epidemiol Infect 1997, 118:259-266.
41. Kramer A, Biggar RJ, Hampl H, et al. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific. Am J Epidemiol 1992, 136:71-80.